Deuruxolitinib - Concert Pharmaceuticals
Alternative Names: C-21543 phosphate; CTP-543; CTP-543 phosphate; D8- ruxolitinib phosphate; D8-ruxolitinib; Deuruxolitinib phosphate; Deuterated ruxolitinib; Deuterium ruxolitinib analogue; Ruxolitinib deuterated - Concert PharmaceuticalsLatest Information Update: 14 May 2024
At a glance
- Originator Concert Pharmaceuticals
- Class 2 ring heterocyclic compounds; Cyclopentanes; Nitriles; Organic deuterium compounds; Pyrazoles; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules
- Mechanism of Action Janus kinase 1 inhibitors; Janus kinase-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Alopecia areata
Most Recent Events
- 08 Mar 2024 Efficacy data from the phase III THRIVE-AA2 trial in Alopecia areata were presented at the American Academy of Dermatology annual Meeting 2024 (AAD-2024)
- 05 Dec 2023 Aclaris Therapeutics enters into a patent license agreement for Deuruxolitinib from Sun Pharmaceutical Industries
- 15 May 2023 Concert Pharmaceuticals completes a phase II trial for Alopecia areata in USA (PO) (NCT04784533)